Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

NCT01262118 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: CP-690,550 (tasocitinib)

Sponsor

Pfizer